Literature DB >> 10609533

Flavobacterium spp. organisms as opportunistic bacterial pathogens during advanced HIV disease.

R Manfredi1, A Nanetti, M Ferri, A Mastroianni, O V Coronado, F Chiodo.   

Abstract

OBJECTIVE: To assess the role of Flavobacterium spp. infection in patients with HIV disease.
METHODS: Clinical charts of 2412 consecutive HIV-infected patients hospitalized in a 8-year period were retrospectively reviewed, to identify all cases of Flavobacterium spp. infections, and to evaluate their occurrence and outcome according to several epidemiological, clinical, and laboratory parameters.
RESULTS: Six patients out of 2412 (0.25%), developed Flavobacterium spp. complications: septicaemia in five cases, and pneumonia in the remaining patient, with F. meningosepticum and F. odoratum isolated in two cases and one case, respectively, and unnamed Flavobacterium spp. organisms in the remaining three cases. Flavobacterium spp. organisms were responsible for six out of 1939 overall episodes of non-mycobacterial bacterial diseases observed in our patient group (0.31%). All patients were severely immunocompromised, showing a prior diagnosis of AIDS, a mean CD4+ lymphocyte count of 64.2 (range 12-187) cells/microl, and a mean neutrophil count of 1.143 (range 700-1600) cells (range 700-1600) cells/microl. Antibiotic, corticosteriod, or cotrimoxazole treatment was carried out during the month preceding disease onset by three, two and five patients, respectively. Community-acquired and nosocomial Flavobacterium spp. disease were equally frequent, but the latter occurred with a significantly lower mean neutrophil and CD4+ cell count. Antimicrobial susceptibility assays showed complete sensitivity to ciprofloxacin, and variable resistance to ureidopenicillins, ceftazidime, imipenem, aztreonam, and aminoglycosides. An appropriate antimicrobial regimen obtained clinical and microbiological cure in all cases, in absence of related mortality or relapses.
CONCLUSIONS: Since only one episode of HIV-associated F. (Sphingobacterium) multivorum complication has been described to date, our series represents the largest one dealing with Flavobacterium spp. infection in the setting of HIV disease. Our experience suggests that Flavobacterium spp. organisms may play a pathogenic role in patients with advanced HIV disease, even when some commonly recognized risk factors are lacking (i.e. indwelling catheters, instrumentation, IV drug abuse), while a very low CD4+ lymphocyte count, leukopaenia-neutropaenia, and concurrent AIDS-related infectious complications may act as important predisposing factors. In view of the infrequent occurrence of these infections, early suspicion is essential for both clinicians and microbiologists facing immunocompromised patients at risk for invasive bacterial complications. Flavobacterium spp. organisms should be taken into consideration as nosocomial- or community-acquired opportunistic pathogens, due to their relationship with advanced immunodeficiency and their elevated resistance to many antimicrobial agents commonly used against Gram-negative bacterial pathogens.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10609533     DOI: 10.1016/s0163-4453(99)90007-5

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  13 in total

1.  Necrotizing fasciitis and septic shock related to the uncommon gram-negative pathogen Sphingobacterium multivorum.

Authors:  D Grimaldi; A Doloy; J Fichet; E Bourgeois; B Zuber; A Wajsfisz; J P Mira; C Poyart; F Pène
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

2.  Shear rate moderates community diversity in freshwater biofilms.

Authors:  Alexander H Rickard; Andrew J McBain; Amy T Stead; Peter Gilbert
Journal:  Appl Environ Microbiol       Date:  2004-12       Impact factor: 4.792

3.  Antigenic characterization of the fish pathogen Flavobacterium psychrophilum.

Authors:  E M Crump; M B Perry; S C Clouthier; W W Kay
Journal:  Appl Environ Microbiol       Date:  2001-02       Impact factor: 4.792

4.  MYROIDES INFECTION IN A BABOON AFTER PROLONGED PIG KIDNEY GRAFT SURVIVAL.

Authors:  Hong Liu; Hayato Iwase; Martin Wijkstrom; Jagjit Singh; Edwin Klein; Robert Wagner; Abhinav Humar; William Pasculle; David K C Cooper
Journal:  Transplant Direct       Date:  2015-05

5.  Characterization of strong promoters from an environmental Flavobacterium hibernum strain by using a green fluorescent protein-based reporter system.

Authors:  S Chen; M Bagdasarian; M G Kaufman; E D Walker
Journal:  Appl Environ Microbiol       Date:  2006-12-22       Impact factor: 4.792

6.  Survey on Carbapenem-Resistant Bacteria in Pigs at Slaughter and Comparison with Human Clinical Isolates in Italy.

Authors:  Silvia Bonardi; Clotilde Silvia Cabassi; Gerardo Manfreda; Antonio Parisi; Enrico Fiaccadori; Alice Sabatino; Sandro Cavirani; Cristina Bacci; Martina Rega; Costanza Spadini; Mattia Iannarelli; Cecilia Crippa; Ferdinando Ruocco; Frédérique Pasquali
Journal:  Antibiotics (Basel)       Date:  2022-06-07

7.  Structure and characterization of flavolipids, a novel class of biosurfactants produced by Flavobacterium sp. strain MTN11.

Authors:  Adria A Bodour; Claudia Guerrero-Barajas; Beth V Jiorle; Mark E Malcomson; Amanda K Paull; Arpad Somogyi; Long N Trinh; Robert B Bates; Raina M Maier
Journal:  Appl Environ Microbiol       Date:  2004-01       Impact factor: 4.792

8.  Molecular characterization of membrane-associated soluble serine palmitoyltransferases from Sphingobacterium multivorum and Bdellovibrio stolpii.

Authors:  Hiroko Ikushiro; Mohammad Mainul Islam; Hiromasa Tojo; Hideyuki Hayashi
Journal:  J Bacteriol       Date:  2007-06-08       Impact factor: 3.490

Review 9.  The structural diversity of carbohydrate antigens of selected gram-negative marine bacteria.

Authors:  Evgeny L Nazarenko; Russell J Crawford; Elena P Ivanova
Journal:  Mar Drugs       Date:  2011-10-14       Impact factor: 6.085

10.  Sphingobacterium multivorum: case report and literature review.

Authors:  F Barahona; J Slim
Journal:  New Microbes New Infect       Date:  2015-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.